基因多态性与铂类药物毒性反应研究进展

中国临床药理学与治疗学 ›› 2014, Vol. 19 ›› Issue (9): 1051-1056.

基因多态性与铂类药物毒性反应研究进展

郑艺, 尹继业, 周宏灏, 刘昭前

中南大学湘雅医院临床药理研究所,中南大学临床药理研究所, 遗传药理学湖南省重点实验室,长沙 410078,湖南

收稿日期:2013-10-30 修回日期:2014-06-11 出版日期:2014-09-26 发布日期:2014-09-26
通讯作者: 刘昭前,男,博士,博士生导师,研究方向:遗传药理学与药物基因组学。Tel: 0731-84805380 E-mail: liuzhaoqian63@126.com
作者简介:郑艺,女,硕士研究生,研究方向:遗传药理学与药物基因组学。 Tel: 0731-84805380 E-mail: lizhi1990312@163.com
基金资助:
国家高技术研究发展计划(863计划)(2012AA02A517); 国家自然科学基金(81173129, 81373490); 湖南省自然科学创新群体基金(12JJ7006)

Advances in relationship of genetic polymorphism with the toxicity caused by platinum-based therapy

ZHENG Yi, YIN Ji-ye, ZHOU Hong-hao, LIU Zhao-qian

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Institute of Clinical Pharmacology,Central Soputh University, Human Key Laboratory of Pharmacogenetics,Changsha 410078,Hunan,China

Received:2013-10-30 Revised:2014-06-11 Online:2014-09-26 Published:2014-09-26

摘要/Abstract

摘要： 铂类药物广泛应用于肺癌、大肠癌、卵巢癌、乳腺癌等多种癌症的治疗,取得显著疗效的同时也不可避免地给患者带来严重的毒副反应。临床研究发现,在化疗方案与用药剂量相同的情况下,铂类化疗导致的毒性具有较大的个体差异,而这种差异在一定程度上与个体遗传多态性相关。本文就铂类药物转运体、代谢酶、DNA损伤修复等相关基因多态与铂类药物化疗毒性之间的相关性作一综述。

关键词: 药物基因组学, 毒副反应, 铂类药物

Abstract: Platinum-based therapy are widely used in treating lots of cancers such as lung cancer, colorectal cancer, ovarian cancer and breast cancer. Although the efficacy of platinum drugs are quite notable in clinical practice, serious toxicity are inevitable. Clinical research have revealed that a wide inter-individual variability in the toxicity caused by Platinum-based therapy exists and this variability may partly due to individual genetic variations. This review summarizes the relationship between the polymorphisms of genes encoding platinum-based drug transporters, platinum-based drug-metabolizing enzymes and DNA repair enzymes and toxicity of platinum-based drugs.

Key words: pharmacogenetics, toxicity, platinum-based therapy

中图分类号:

R969.8

郑艺, 尹继业, 周宏灏, 刘昭前. 基因多态性与铂类药物毒性反应研究进展[J]. 中国临床药理学与治疗学, 2014, 19(9): 1051-1056.

ZHENG Yi, YIN Ji-ye, ZHOU Hong-hao, LIU Zhao-qian. Advances in relationship of genetic polymorphism with the toxicity caused by platinum-based therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 1051-1056.

参考文献 38

[1]	Cepeda V, Fuertes MA, Castilla J.Biochemical mechanisms of cisplatin cytotoxicity[J]. Anticancer Agents Med Chem, 2007, 7(1): 3-18.
[2]	赵钢涛, 杨凡, 丁媛媛, 等. 基因单核苷酸多态性对非小细胞肺癌铂类化疗敏感性影响的研究进展[J]. 中国临床药理学与治疗学, 2010, 15(6): 715-720.
[3]	Rabik CA, Dolan ME.Molecular mechanisms of resistance and toxicity associated with platinating agents[J]. Cancer Treat Rev, 2007, 33(1): 9-23.
[4]	Garmann D, Warnecke A, Kalayda GV, et al.Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells[J]. J Control Release, 2008, 131(2): 100-106.
[5]	Arnesano F, Scintilla S, Natile G.Interaction between platinum complexes and a methionine motif found in copper transport proteins[J]. Angew Chem Int Ed Engl, 2007, 46(47): 9062-9064.
[6]	Ishida S, Lee J, Thiele DJ, et al.Uptake of the anticancer drug cisplatin mediated by the copper transporter ctr1 in yeast and mammals[J]. Proc Natl Acad Sci U S A, 2002, 99(22): 14298-14302.
[7]	More SS, Akil O, Ianculescu AG, et al.Role of the copper transporter, ctr1, in platinum-induced ototoxicity[J]. J Neurosci, 2010, 30(28): 9500-9509.
[8]	Xu X, Ren H, Zhou B, et al.Prediction of copper transport protein 1 (ctr1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (nsclc) patients[J]. Lung Cancer, 2012, 77(2): 438-442.
[9]	Holzer AK, Samimi G, Katano K, et al.The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells[J]. Mol Pharmacol, 2004, 66(4): 817-823.
[10]	Filipski KK, Loos WJ, Verweij J, et al.Interaction of cisplatin with the human organic cation transporter 2[J]. Clin Cancer Res, 2008, 14(12): 3875-3880.
[11]	Filipski KK, Mathijssen RH, Mikkelsen TS, et al.Contribution of organic cation transporter 2 (oct2) to cisplatin-induced nephrotoxicity[J]. Clin Pharmacol Ther, 2009, 86(4): 396-402.
[12]	Fujita T, Urban TJ, Leabman MK, et al.Transport of drugs in the kidney by the human organic cation transporter, oct2 and its genetic variants[J]. J Pharm Sci, 2006, 95(1): 25-36.
[13]	Zhang J, Zhou W.Ameliorative effects of slc22a2 gene polymorphism 808 g/t and cimetidine on cisplatin-induced nephrotoxicity in chinese cancer patients[J]. Food Chem Toxicol, 2012, 50(7): 2289-2293.
[14]	Iwata K, Aizawa K, Kamitsu S, et al.Effects of genetic variants in slc22a2 organic cation transporter 2 and slc47a1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events[J]. Clin Exp Nephrol, 2012, 16(6): 843-851.
[15]	Homolya L, Varadi A, Sarkadi B.Multidrug resistance-associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate[J]. Biofactors, 2003, 17(1/2/3/4): 103-114.
[16]	Han B, Gao G, Wu W, et al.Association of abcc2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients[J]. Lung Cancer, 2011, 72(2): 238-243.
[17]	Schwartz JB.The influence of sex on pharmacokinetics[J]. Clin Pharmacokinet, 2003, 42(2): 107-121.
[18]	Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with p-glycoprotein expression and activity in vivo[J]. Proc Natl Acad Sci U S A, 2000, 97(7): 3473-3478.
[19]	Illmer T, Schuler US, Thiede C, et al.Mdr1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients[J]. Cancer Res, 2002, 62(17): 4955-4962.
[120]	Chen S, Huo X, Lin Y, et al.Association of mdr1 and ercc1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients[J]. Int J Hyg Environ Health, 2010, 213(2): 140-145.
[21]	Sheehan D, Meade G, Foley VM, et al.Structure, function and evolution of glutathione transferases: Implications for classification of non-mammalian members of an ancient enzyme superfamily[J]. Biochem J, 2001, 360(Pt 1): 1-16.
[22]	Goto S, Iida T, Cho S, et al.Overexpression of glutathione s-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells[J]. Free Radic Res, 1999, 31(6): 549-558.
[23]	Moyer AM, Salavaggione OE, Wu TY, et al.Glutathione s-transferase p1: gene sequence variation and functional genomic studies[J]. Cancer Res, 2008, 68(12): 4791-4801.
[24]	Chen YC, Tzeng CH, Chen PM, et al.Influence of gstp1 i105v polymorphism on cumulative neuropathy and outcome of folfox-4 treatment in asian patients with colorectal carcinoma[J]. Cancer Sci, 2010, 101(2): 530-535.
[25]	Ruzzo A, Graziano F, Loupakis F, et al.Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line folfox-4 chemotherapy[J]. J Clin Oncol, 2007, 25(10): 1247-1254.
[26]	Joerger M, Burgers SA, Baas P, et al.Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study[J]. Cancer, 2012, 118(9): 2466-2475.
[27]	Khrunin AV, Moisseev A, Gorbunova V, et al.Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients[J]. Pharmacogenomics J, 2010, 10(1): 54-61.
[28]	Marsh S, Paul J, King CR, et al.Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the scottish randomised trial in ovarian cancer[J]. J Clin Oncol, 2007, 25(29): 4528-4535.
[29]	Enzlin JH, Scharer OD.The active site of the DNA repair endonuclease xpf-ercc1 forms a highly conserved nuclease motif[J]. EMBO J, 2002, 21(8): 2045-2053.
[30]	Suk R, Gurubhagavatula S, Park S, et al.Polymorphisms in ercc1 and grade 3 or 4 toxicity in non-small cell lung cancer patients[J]. Clin Cancer Res, 2005, 11(4): 1534-1538.
[31]	Tzvetkov MV, Behrens G, O'Brien VP, et al. Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ercc1 polymorphisms[J]. Pharmacogenomics, 2011, 12(10): 1417-1427.
[32]	Giachino DF, Ghio P, Regazzoni S, et al.Prospective assessment of xpd lys751gln and xrcc1 arg399gln single nucleotide polymorphisms in lung cancer[J]. Clin Cancer Res, 2007, 13(10): 2876-2881.
[33]	de Boer J, Hoeijmakers JH. Nucleotide excision repair and human syndromes[J]. Carcinogenesis, 2000, 21(3): 453-460.
[34]	Despras E, Pfeiffer P, Salles B, et al.Long-term xpc silencing reduces DNA double-strand break repair[J]. Cancer Res, 2007, 67(6): 2526-2534.
[35]	Sakano S, Hinoda Y, Sasaki M, et al.Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer[J]. Pharmacogenomics, 2010, 11(10): 1377-1387.
[36]	Zhang L, Gao G, Li X, et al.Association between single nucleotide polymorphisms (snps) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy[J]. PLoS One, 2012, 7(10): e48350.
[37]	El-Khamisy SF, Masutani M, Suzuki H, et al.A requirement for parp-1 for the assembly or stability of xrcc1 nuclear foci at sites of oxidative DNA damage[J]. Nucleic Acids Res, 2003, 31(19): 5526-5533.
[38]	Wang Z, Xu B, Lin D, et al.Xrcc1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in chinese population[J]. Lung Cancer, 2008, 62(1): 99-104.